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This study investigated whether D,L-cis-2,3-Pyrrolidine dicarboxylate (D,L-cis-2,3-PDC), a new glutamate analogue, alters glutamate
binding to cerebral plasma membranes and whether N-methyl-D-aspartate (NMDA) receptors are involved in the convulsant effect of this
compound. D,L-cis-2,3-PDC reduced sodium-independent [3H]-L-glutamate binding to lysed membrane preparations from adult rat cortex
and had no effect on sodium-dependent glutamate binding. Intracerebroventricular administration of D,L-cis-2,3-PDC (7.5–25 nmol/5 Al)
induced generalized tonic–clonic convulsions in mice in a dose-dependent manner. The coadministration of MK-801 (7 nmol/2.5 Al), with
D,L-cis-2,3-PDC (16.5 nmol/2.5 Al), fully protected the animals against D,L-cis-2,3-PDC-induced convulsions, while the coadministration of
DNQX (10 nmol/2.5 Al) increased the latency to convulsions but did not alter the percentage of animals that had convulsions. These results
suggest that D,L-cis-2,3-PDC-induced effects are mediated predominantly by NMDA receptors.D 2003 Elsevier Inc. All rights reserved.Keywords: Binding; Convulsion; Glutamate; MK-801; DNQX; Intracerebroventricular administration1. Introduction
Glutamate and aspartate are the predominant excitatory
amino acid (EAA) neurotransmitters in the mammalian brain
(Kanai et al., 1993; Szatkowski and Attwell, 1994). The
EAAs activate a family of ligand-gated ion channels, called
ionotropic receptors [e.g., N-methyl-D-aspartate (NMDA),
kainic acid (KA), and alfa-amino-3-hydroxy-5-methyl-4-
isoxazolepropionate (AMPA)], and a family of receptors
coupled through GTP-binding proteins to a variety of intra-
cellular signaling molecules, called ‘‘metabotropic’’ recep-
tors (Conn and Patel, 1994; Hollman and Heinemann, 1994;
Nakanishi, 1994; Nicolletti et al., 1996). Metabotropic
receptors are activated by ligands such as trans-1-amino-
cyclopentane-1,3-dicarboxylate (1S,3R-ACPD), L-2-amino-
4-phosphonobutyric acid (L-AP-4), ibotenate, and quisqualic
acid (QA) (Hollman and Heinemann, 1994). EAA receptors0091-3057/$ – see front matter D 2003 Elsevier Inc. All rights reserved.
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E-mail address: cf.mello@smail.ufsm.br (C.F. Mello).participate not only in fast excitatory transmission but also in
more complex signaling processes, such as those required for
synaptic plasticity and higher cognitive functions (Daw et
al., 1993; Collingridge and Bliss, 1995; Cotman et al., 1995).
In contrast to these normal signaling pathways, excessive
activation of the ionotropic EAA receptors can trigger a
cascade of events that eventually leads to neuronal death.
This process, referred to as excitotoxicity, is thought to be an
underlying pathological mechanism in a wide variety of
neurological insults and degenerative disorders, such as
ischemia, trauma, hypoglycemia, epilepsy, and Huntington’s
and Parkinson’s diseases (Choi, 1990, 1994; Meldrum, 1993;
Rothman and Olney, 1995).
L-Glutamate has an acyclic structure that has a free
rotation at the space capable of assuming a wide range of
conformations. Accumulating evidence suggests that gluta-
mate may bind to each of the known EAA receptors and
transporters in a distinct conformation. A cornerstone in the
identification and characterization of the EAA receptors has
been the utilization of conformationally constrained ana-
logues of L-glutamate and L-aspartate. The application of the
Fig. 1. Comparison of conformational mobility of aspartate to cis-2,3-PDC.
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partate and glutamate is based on the construction of deriv-
atives on a cyclic framework, which imposes more restricted
angles on key structural and functional groups. The concept
is best illustrated by the Fig. 1 where cis-2,3-PDC is
compared to aspartate with regard to its flexibility (Watkins
et al., 1990; Ortwine et al., 1992; Chamberlin and Bridges,
1993). By positioning the carboxylate groups at differing
points around the ring, the carbon backbone of glutamate and
aspartate can be embedded within a cyclic structure (Willis et
al., 1997). These more rigid analogues can attain fewer of the
required conformations and very often exhibit greater selec-
tivity of binding than glutamate itself. These compounds
become valuable not only in further refining the pharmaco-
logical requirements of the receptor classes but as probes of
synaptic signaling and excitotoxic pathology (Willis et al.,
1996). Previous studies have identified (2S,4S)-pyrrolidine
dicarboxylate (L-trans-2,4-pyrrolidine dicarboxylate: L-trans-
2,4-PDC) as a potent and selective inhibitor of the high-
affinity, sodium-dependent glutamate transporter (Bridges et
al., 1991). Positioning the distal COOH at the C3 position
yielded L-cis-2,3-PDC (Humphrey et al., 1994) and L-trans-
2,3-PDC. This latest proved to be a weaker uptake inhibitor
but a potent NMDA agonist (Willis et al., 1996) whose
excitotoxic potency and selectivity towards NMDA recep-
tors are further increased by the introduction of a methyl
group to the 5V position of the pyrrolidine ring (Willis et al.,
1997). Nevertheless, the effects of cis pyrrolidine dicarbox-
ylate derivatives on the glutamatergic system were not
investigated to date. In the present study, we investigated
whether D,L-cis-2,3-Pyrrolidine dicarboxylate (D,L-cis-2,3-
PDC; Fig. 2), a new glutamate analogue and a L-trans-2,3-
PDC diastereoisomer, causes convulsions and whether
NMDA receptors are involved in the convulsant effect of
this compound. In addition, due to the presently reported
protective effect of MK-801 against D,L-cis-2,3-PDC in-
duced-convulsions, we evaluated whether it alters glutamate
binding to cerebral plasma membranes.Fig. 2. Chemical structures of NMDA, L-trans-2,3-PDC, D,L-cis-2,3-PDC.2. Material and methods
2.1. Reagents
All reagents were acquired from Sigma, MA, except
[3H]-L-glutamic acid, which was purchased from Amersham
Pharmacia Biotech; MK-801, which was purchased fromRBI; and D,L-cis-2,3-PDC, which was synthesized by Car-
pes et al. (1997).
2.2. Animals
Adult male Wistar rats (230–250 g) and male albino
mice (30–40 g), maintained in a 12:12-h dark/light cycle at
controlled temperature (22F 1 jC) with lab chow and tap
water ad libitum, were used.
2.3. Membrane preparation
Membrane preparation was carried out as described by
Emanuelli et al. (1998). Adult male Wistar rats were killed
by decapitation; cerebral cortices were removed and ho-
mogenized in 20 volumes (ml/g of wet tissue) of 10 mM
Tris–acetate buffer (pH 7.4) containing 320 mM sucrose,
and 1 mM MgCl2 using a hand-operated glass homogenizer.
The homogenate was centrifuged at 1000 g for 15 min
and the pellet was resuspended in 20 volumes (ml/g of wet
tissue) of the same buffer and centrifuged again. The second
pellet was discarded and the supernatant fractions were
pooled and centrifuged at 27,000 g for 15 min. The
resulting pellet was lysed in 20 volumes of 10 mM Tris–
acetate buffer (pH 7.4) for 30 min and centrifuged at
27,000 g for 15 min. This pellet was washed three times
in 20 volumes of 10 mM Tris–acetate buffer (pH 7.4) at
27,000 g for 15 min. The final pellet was resuspended in
three volumes of 10 mM Tris–acetate buffer (pH 7.4). All
steps were carried out at 4 jC and the membranes were
frozen at  20 jC for no more than 1 month. On the day of
binding assay, the membranes were rapidly thawed in a
water bath (37 jC), homogenized with 3 volumes of 10 mM
Tris–acetate buffer (pH 7.4), and centrifuged at 27,000 g
for 15 min. The resulting pellet was resuspended in three
volumes (ml/ml of thawed membrane) of the same buffer,
preincubated at 37 jC for 30 min, and centrifuged at
27,000 g for 15 min. The pellet was resuspended in three
volumes of 10 mM Tris–acetate buffer, washed four times
in three volumes of the same buffer, and centrifuged at
27,000 g for 15 min. The final pellet was resuspended in
the same buffer in order to yield a protein concentration of
1–2 mg/ml and was used for the binding assays.
2.4. [3H]-L-glutamate binding
Sodium-dependent and -independent [3H]-L-glutamate
binding to cerebral plasma membranes was investigated
Fig. 3. Effect of D,L-cis-2,3-PDC on [3H]-L-glutamate binding in rat brain
plasma membranes. Results are presented as means (S.E.M.) of three
experiments and are expressed as activity percentage of control. * Sig-
nificantly different from control ( P < .05—SNK test).
Table 1









0.85% NaCl 600 (600–600) 0/7 (0%) 0/7 (0%)
D,L-cis-2,3-PDC
2.5 nmol 600 (600–600) 0/8 (0%) 0/8 (0%)
7.5 nmol 68.0 (20.0–264.0)# 5/6 (83.3%) * 0/6 (0%)
25 nmol 10.5 (3.7–15.2)# 9/9 (100%) * 3/9 (33.4%) *
n= 6–9 animals in each group; ncv—number of animals which had
convulsions; nd—number of animals that died; nt—total number of animals.
* P< .05 compared to 0.85% NaCl (Fisher’s test).
# P < .0001 compared to 0.85% NaCl (Kruskal–Wallis test).
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were incubated in a 0.5-ml reaction mixture containing 50
mM Tris–acetate buffer (pH 7.4), 40 nM [3H]-L-glutamate,
and 0, 0.05, 0.5, 5, 50, and 500 AM D,L-cis-2,3-PDC
(dissolved in water, pH adjusted to 7.4 with KOH). Sodi-
um-dependent binding was carried out in the same incuba-
tion medium described above, except that it contained 150
mM sodium acetate. Incubation was carried out at 30 jC for
30 min and the reaction was stopped by filtration using GF/
B glass microfiber filters. Dried filters were transferred to
eppendorf tubes containing scintillation liquid, and the
radioactivity was determined with a Packard scintillation
spectrometer at 40–45% efficiency. Specific binding was
calculated as the difference between total binding and
nonspecific binding, which was measured in the presence
of a 10,000-fold excess (4 mM) of the unlabeled L-gluta-
mate. All determinations were made in triplicate. Protein
concentration was measured using bovine serum albumin as
standard (Bradford, 1976). Data were analyzed by one-way
analysis of variance (ANOVA) followed by the Student–
Newman–Keuls multiple range test, when appropriate.
Standard errors were less than 10%.
2.5. Behavioral effects of D,L-cis-2,3-PDC on mice
Freehand intracerebroventricular injections into the lat-
eral ventricles of the conscious mice were made using a 29G
needle attached to a 10-Al Hamilton syringe (3 mm of the
needle tip exposed) according to Clark et al. (1988). The site
of injection was an imaginary line drawn through the
anterior lobe of the ears and from an imaginary midsagittal
line, and the whole injection procedure was completed
within 5–10 s in order to minimize discomfort and pain.
Immediately after behavioral evaluation, the animals were
decapitated and had the site of the intracerebroventricular
injection confirmed by needle track verification with a PZO
MST 131 stereomicroscope. Only data from animals with
the needle track aiming the lateral ventricle were considered.
In those experiments designed to evaluate the convulsantaction of D,L-cis-2,3-PDC, the animals were injected (intra-
cerebroventricular) with 5 Al of D,L-cis-2,3-PDC (2.5, 7.5,
and 25 nmol) or 0.85% NaCl. Immediately thereafter, the
animals were individually placed in a round open field (35
cm of internal diameter) and observed for 10 min for the
appearance of tonic–clonic convulsions. The latency for the
first convulsive episode (a full motor seizure with loss of
postural control, usually reported as a Class 5 motor seizure
according to the Racine scale) and the percent of animals
that presented convulsions or death were recorded (Racine,
1972). For statistical purposes, the animals that did not
present tonic–clonic convulsions up to 600 s were attributed
a score of 600. The involvement of NMDA or AMPA and
KA receptors in the D,L-cis-2,3-PDC-induced convulsions
was assessed by coinjecting the animals (intracerebroven-
tricular) with 7.0 nmol MK-801 or 10 nmol DNQX and 16.5
nmol D,L-cis-2,3-PDC or 0.85% NaCl alone and 0.85%
NaCl with the drugs above, in 2.5 Al plus 2.5 Al volumes
in the same syringe, separated by an air bubble (0.1 Al). The
animals were immediately transferred to the open field and
observed for 10 min for the signs of convulsions, as
described above. The D,L-cis-2,3-PDC dose was chosen on
the basis of its effectiveness to cause convulsions in 100%
of the animals without death (the dose–effect curve and
pilot experiments).3. Results
3.1. Binding
Fig. 3 shows the effect of D,L-cis-2,3-PDC on sodium-
independent [3H]-L-glutamate binding to cerebral plasma
membranes. D,L-cis-2,3-PDC reduced sodium-independent
[3H]-L-glutamate binding by 50% in membrane prepara-
tions from adult rat cortex [F(5,12) = 28.1, P < .00001
ANOVA, considering D,L-cis-2,3-PDC concentrations (0–
500 AM) as a within-subject factor]. Partitioning of the sum
of squares into trend components revealed a significant
linear trend [F(1,12) = 112.2, P < .001], indicating that
sodium-independent [3H]-L-glutamate binding decreased
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Interestingly, D,L-cis-2,3-PDC had no effect on sodium-
dependent [3H]-L-glutamate binding (data not shown).
3.2. Behavioral evaluation
Intracerebroventricular administration of 2.5 nmol of D,L-
cis-2,3-PDC did not cause convulsions, while 7.5 nmol of
D,L-cis-2,3-PDC induced generalized tonic–clonic convul-
sions, which lasted a few minutes. D,L-cis-2,3-PDC (25
nmol) induced long-lasting generalized tonic–clonic con-
vulsions immediately after its injection. Table 1 shows the
effect of the injection of increasing amounts of D,L-cis-2,3-
PDC (0, 2.5 or 7.5, and 25 nmol icv) on convulsive
behavior. Statistical analysis (H = 23.05, df = 3, P < .0001;
Kruskal–Wallis H test) revealed that increasing amounts of
D,L-cis-2,3-PDC decreased the latency to convulsion and
increased the percentage of animals that presented convul-
sions and death (P < .05, Fisher test). The most of animals
that received 25 nmol D,L-cis-2,3-PDC (66.6%) remained
alive after a 24-h period.
The involvement of NMDA receptors on the convulsant
effect of D,L-cis-2,3-PDC was assessed by coadministrating
MK-801 (7 nmol/ 2.5 Al), a noncompetitive NMDA receptor
antagonist, with D,L-cis-2,3-PDC (16.5 nmol/ 2.5 Al). The
coadministration of MK-801 protected the animals against
D,L-cis-2,3-PDC-induced convulsions, measured by the fre-
quency of convulsions (P < .05, Fisher test—Table 2) and
by the latency to the first convulsive episode (H = 19.55,
df = 3, P < .0001; Kruskal-Wallis H test).
The involvement of AMPA and KA receptors on the
convulsant effect of D,L-cis-2,3-PDC was assessed by coad-
ministrating DNQX (10 nmol/2.5 Al), a competitive AMPA
and KA receptor antagonist, with D,L-cis-2,3-PDC (16.5
nmol/2.5 Al). The coadministration of DNQX afforded a
slight protection against D,L-cis-2,3-PDC-induced convul-
sions since it increased the latency to convulsion (H = 23.72,
df = 3, P < .0001; Kruskal–Wallis H test—Table 2).Table 2
Effect of MK-801 (7 nmol) or DNQX (10 nmol) on D,L-cis-2,3-PDC-





0.85% NaCl + 0.85% NaCl 600 (600–600) 0/6 (0%)
0.85% NaCl +D,L-cis-2,3-PDC
(16.5 nmol)
14.0 (11.0—16.0) * 6/6 (100%) *
MK-801 + 0.85% NaCl 600 (600–600) 0/5 (0%)
MK-801 +D,L-cis-2,3-PDC
(16.5 nmol)
600 (600–600) 0/5 (0%)
DNQX+ 0.85% NaCl 600 (600–600) 0/7 (0%)
DNQX+D,L-cis-2,3-PDC
(16.5 nmol)
26.0 (16.0–38.0) * 7/7 (100%) *
n= 5–7 animals in each group; ncv—number of animals which had
convulsions; nt—total number of animals. D,L-cis-2,3-PDC (16.5 nmol) did
not cause death.
* P< .0001 compared to NaCl–NaCl (Kruskal–Wallis test).We also assessed the locomotor behavior of the animals.
Statistical analysis of open-field data (one-way ANOVA)
revealed that coadministration of MK-801 increased immo-
bility scores [F(3,17) = 5.63, P < .05] and had no effect on
number of crossing [F(3,17) = 2.41, P>.05] or rearing
responses [F(3,17) = 2.38, P>.05].4. Discussion
The action of L-glutamate at the various EAA receptors
plays a central role in both neuronal communication and
CNS pathology (Cotman et al., 1995). Given their role, it is
not surprising that considerable attention has focused on
EAA receptor pharmacology and on the development of
selective agonists and antagonists of these receptors. It is
remarkable that recent progress has expanded the library of
EAA analogues beyond those originally used to delineate
the basic receptor classes (e.g., NMDA, KA, and AMPA).
These newer agonists have been valuable in characterizing
receptor channel properties, elucidating intracellular pro-
cesses triggered by receptor activation, and associating
specific pathological cascades with individual types of
receptors (Ishida and Shinozaki, 1988; Debonnel et al.,
1989; Shinozaki et al., 1989; Lanthorn et al., 1990; Kudo
et al., 1991; Schoepp et al., 1991, 1994; Madsen et al.,
1996).
In the present study, we demonstrated that D,L-cis-2,3-
PDC, a glutamate analogue, inhibited only sodium-indepen-
dent [3H]-L-glutamate binding in brain plasma membranes,
indicating an interaction with glutamate receptors. These
results suggest that this compound, differently from its
diastereoisomer L-trans-2,3-PDC (Willis et al., 1996) and
L-trans-2,4-PDC (Bridges et al., 1991), does not interact
with glutamate uptake binding sites. One should be aware,
however, that such a lack of effect of D,L-cis-2,3-PDC on
sodium-dependent binding does not imply a lack of effect of
this compound on amino acid uptake or release since
binding studies do not directly address functional activity
but do identify specific sites of action. Nevertheless, the fact
that a cis pyrrolidine dicarboxylate derivative does not alter
sodium-dependent [3H]-L-glutamate binding while trans
isomers alter it suggests that the cis configuration of the
carboxyl groups in the pyrrolidine ring affords some selec-
tivity towards nontransport glutamate binding sites. It
remains to be determined whether D,L-cis-2,3-PDC selec-
tively binds to ionotropic or metabotropic receptors, but
pharmacological evidence supports the involvement of
NMDA receptors in the convulsant effects of D,L-cis-2,3-
PDC, as discussed below.
It is remarkable that the intracerebral injection of D,L-cis-
2,3-PDC caused generalized tonic–clonic convulsions in all
mice in a dose-dependent manner (see Table 1). Moreover,
these convulsions were completely prevented by the coad-
ministration of the NMDA receptor antagonist MK-801, but
not by DNQX, a competitive AMPA and KA receptor
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D,L-cis-2,3-PDC-induced convulsions. These results indicate
that D,L-cis-2,3-PDC cause convulsions by activating
NMDA receptors, and that the participation non-NMDA
ionotropic receptors in the convulsant action of D,L-cis-2,3-
PDC is of minor relevance.
In conclusion, in this study, we report that the glutamate
analogue D,L-cis-2,3-PDC interacts with nontransport gluta-
mate binding sites and causes convulsions in mice, which
seem to be due to the activation of NMDA receptors.
Further studies are still necessary to determine whether this
novel neurotoxin affects other glutamate-related functions as
well as its value as a pharmacological tool.Acknowledgements
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